Harmony Biosciences, a private biopharmaceutical company dedicated to developing and commercializing novel treatment options for people living with rare diseases, opened its 15,651 square foot headquarters in Plymouth Meeting, Pennsylvania.

The company is currently focusing on the registration and commercialization of its investigational product for the treatment of narcolepsy. Since inception, Harmony has grown to a current total of 42 staff members, with plans to significantly expand its workforce over the coming years.

"At Harmony, we take seriously our responsibilities and commitments to those who live with rare diseases, our employees, business partners and the broader life sciences community in our headquarters state of Pennsylvania," said John C. Jacobs, President & CEO. "We were deeply honored that Governor Wolf participated in today's ribbon cutting for our new facility, which speaks to his ongoing support of economic development, jobs creation and the growth of innovative, emerging companies in the biopharmaceutical hub of Philadelphia."

"From our founding, Pennsylvania and Pennsylvania-based companies have always been trail blazers in the life sciences," said Governor Tom Wolf. "We as a commonwealth are proud to be the home of so many of the important leaders shaping the healthcare and life sciences industry today. I want to thank Harmony Biosciences for choosing Pennsylvania as the best place to do such important and life-changing work."

"At LSPA (Life Sciences PA), we work to unify Pennsylvania's innovative companies that make the Commonwealth a global life sciences leader," said Chris Molineaux, President & CEO of LSPA. "Today we recognize Harmony Biosciences for the company's entrepreneurial spirit and its contributions to a robust life sciences presence in Pennsylvania, and we congratulate Harmony on its official ribbon cutting at its completed headquarters in Plymouth Meeting, Pennsylvania."